ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
FAIL · Does not pass the screen
71.71 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price71.71 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans slightly to calls (put/call 0.89)
Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 71.71 against the desk's fair-value range, base estimate 121.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.89, read 2026-10-24
Ethical does not pass the values gate
Price71.71 USD
Fair value121.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-18Read Markdown72.28-0.8% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-10-11Read Accumulation71.52+0.3% to today ✓Markdown gives way to Accumulation after a 10% slide in 12 weeks
2026-07-21Read Markdown79.20-9.5% to today ✓Accumulation gives way to Markdown
2026-07-02Read Accumulation81.68-12.2% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ANI Pharmaceuticals, Inc. holds its Markdown at $71.71. Consolidating, no directional conviction, held for 173 days.
As held on the ledger · 2026-10-28
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 173 days
Price at the screen
$71.71
Valuation
15.77 trailing · 7.11 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.50
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
42.84%
Below 33%
Interest-bearing debt is 42.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.63%
Below 33%
Cash held in interest-bearing accounts and securities is 0.6% of assets, under the one-third limit.
Pass
Receivables
39.34%
Below 49%
Money owed to the company is 39.3% of assets, under the 49% limit.
Pass
Revenue purity
1.42%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
ANI Pharmaceuticals,'s business is in a permissible area, but its interest-bearing debt is about 43% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ANIP's ethical verdict changes
Today ANIP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 68.7% margin of safety to the base estimate.
Third-party analyst targets: 9 covering, consensus None. The average target sits +45% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ANIP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markdown$71.71-0.7%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$72.24-0.1%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110. Insiders have been net sellers over the past quarter.
2026-10-18Markdown · changed$72.28+1.1%Entry 10
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 9.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110. Insiders have been net sellers over the past quarter.
2026-10-02Markdown$78.85+7.1%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110. Insiders have been net sellers over the past quarter.
2026-09-21Markdown$73.59-2.0%Entry 7
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110. Insiders have been net sellers over the past quarter.
2026-08-21Markdown$75.12-5.2%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110.
2026-07-21Markdown · changed$79.20-3.0%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110.
2026-07-18Accumulation$81.68+0.0%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110.
2026-07-17Accumulation$81.68+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it buy, with a mean price target of $110.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
